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Background: A promising cancer vaccine involves the fusion of tumor cells with dendritic cells (DCs). As such, a
broad spectrum of both known and unidentified tumor antigens is presented to the immune system in the context
of the potent immunostimulatory capacity of DCs. Murine studies have demonstrated the efficacy of fusion
immunotherapy. However the clinical impact of DC/tumor fusion vaccines has been limited, suggesting that the
immunosuppresive milieu found in patients with malignancies may blunt the efficacy of cancer vaccination. Thus,
novel strategies to enhance fusion vaccine efficacy are needed. Regulatory T cells (Tregs) are known to suppress
anti-tumor immunity, and depletion or functional inactivation of these cells improves immunotherapy in both
animal models and clinical trials. In this study, we sought to investigate whether functional inactivation of
CD4+CD25+FoxP3+ Treg with anti-CD25 monoclonal antibody (mAb) PC61 prior to DC/tumor vaccination would
significantly improve immunotherapy in the murine B16 melanoma model.
Methods: Treg blockade was achieved with systemic PC61 administration. This blockage was done in conjunction
with DC/tumor fusion vaccine administration to treat established melanoma pulmonary metastases. Enumeration
of these metastases was performed and compared between experimental groups using Wilcoxon Rank Sum Test.
IFN-gamma ELISPOT assay was performed on splenocytes from treated mice.
Results: We demonstrate that treatment of mice with established disease using mAb PC61 and DC/tumor fusion
significantly reduced counts of pulmonary metastases compared to treatment with PC61 alone (p=0.002) or
treatment with control antibody plus fusion vaccine (p=0.0397). Furthermore, IFN-gamma ELISPOT analyses reveal
that the increase in cancer immunity was mediated by anti-tumor specific CD4+ T-helper cells, without
concomitant induction of CD8+ cytotoxic T cells. Lastly, our data provide proof of principle that combination
treatment with mAb PC61 and systemic IL-12 can lower the dose of IL-12 necessary to obtain maximal therapeutic
efficacy.
Conclusions: To our knowledge, this is the first report investigating the effects of anti-CD25 mAb administration
on DC/tumor-fusion vaccine efficacy in a murine melanoma model, and our results may aide the design of future
clinical trials with enhanced therapeutic impact.
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Melanoma kills over 8,000 people in the US each year,
and its incidence is increasing faster than that of any
other malignancy, with over 65,000 diagnosed cases last
year (NCI cancer statistics). The mainstay of treatment
remains surgical excision of the primary skin lesion, with
regional lymph node dissection to remove nodal metas-
tases. For subjects with isolated nodal metastases at
presentation, the 5 year survival rate is less than 50%,
and standard treatments in both the adjuvant and
inoperable metastatic disease settings show little to no
survival benefit.
In contrast, immunotherapy with DC-tumor cell
fusion vaccines represents a particularly promising ap-
proach for the treatment of metastatic melanoma. Mel-
anoma cells express a wide spectrum of known as well
as patient-specific tumor-associated antigens and DCs
are the most potent antigen-presenting cells attributable
to their abundant expression of major histocompatibility
complex (MHC) class I and II molecules as well as co-
stimulatory and adhesion molecules which provide sig-
nals 1 and 2 for stimulation of naïve T cells [1]. However,
the induction of primary T-cell responses against tumor-
associated antigens in vivo is critically dependent upon
co-administration of an adjuvant that can provide a 3rd
signal to prevent T-cell tolerance or anergy and hence to
induce T-cell effector function and memory [2]. 3rd sig-
nals include systemic IL-12 [3], agonistic antiOX40- [4],
anti4-1BB- [5] or antagonistic PD-1 [6] monoclonal anti-
bodies (mAbs), as well as DC1-polarizing Toll-like recep-
tor agonists such as poly(I:C) and CpG. [7] The success of
DC/fusion-based cancer vaccination in animal models has
prompted the initiation of several clinical trials, but des-
pite potent induction of anti-tumor T-cell immunity, only
modest clinical responses were observed in a minority of
patients [8]. Thus, it is evident that additional strategies
are needed to improve fusion vaccine efficacy.
A major obstacle to the development of any immuno-
therapeutic approach is the control of immune-balance.
Regulatory T cells (Tregs) are responsible for maintaining
tolerance to self-antigens, and immune homeostasis by
regulating the activation of non-regulatory T cells [9].
Tregs exert their effects through TGF-β [10], IL-10 [11],
CTLA-4 (cytotoxic T-lymphocyte antigen 4) [12], or
through sequestration of IL-2 via expression of CD25 [13],
the α-subunit of the high-affinity IL-2 receptor, and are
defined by their expression of the transcription factor
forkhead box transcription factor 3 (FoxP3) [14]. Recently,
several methods for the depletion or functional inactivation
of Tregs have been developed as part of a multi-pronged
approach to the immunotherapy of melanoma patients.
Treatment with low dose cyclophosphamide resulted in a
reduction of Treg frequencies [15], however Treg elimin-
ation was also associated with a concomitant reduction ofCD8+ T cells and a lack of tumor antigen priming [16].
Administration of CD25-targeted immunotoxins, designed
to have a direct cytocidal action on cells which express the
high-affinity IL-2 receptor, only leads to a modest and
transient reduction in Treg numbers and has achieved
variable results in improving immunotherapy [17,18]. The
fully human mAb Ipilimumab was approved in 2011 by
the FDA for clinical use against melanoma. Ipilumumab
exerts its therapeutic effects through direct enhancement
of CD8+ T-cell function and simultaneous inhibition of
Treg function through blockade of CTLA-4 on both cell
types [19], which makes it hard to delineate its effects on a
DC vaccine that aims to induce primary immune re-
sponses against tumor-associated antigens. Lastly, the
anti-mouse CD25 mAb PC61, as well as the anti-human
CD25 mAbs Basiliximab and Daclizumab, demonstrated a
potent deactivation of Treg suppression that was mediated
through moderate reduction of Treg numbers [20-23] and
functional inhibition through blockade of IL-2 signaling
[24]. Importantly, treatment with anti-CD25 mAbs did
not abrogate tumor antigen-specific immunity elicited by
DC-based vaccines, despite the fact that activated effector
T cells transiently express high levels of CD25. We there-
fore chose to use mAb PC61 in our vaccination studies.
In this report, we demonstrate that administration of
mAb PC61 was an effective means to functionally inacti-
vate Tregs in a murine melanoma model. In addition, we
provide evidence that inactivation of Tregs enhances the
potency of vaccination with DC/tumor cell fusions in a
synergistic fashion, and that the enhancement of anti-
tumor activity was primarily mediated by CD4+ T-
effector cells. Furthermore, our data provide proof of
principle that combination treatment with mAb PC61
and systemic IL-12 can lower the dose of cytokine ne-
cessary to obtain maximal therapeutic efficacy and may
therefore represent a viable strategy to reduce IL-12 me-
diated toxicity in a clinical setting.
Materials and methods
Animals
This work was approved by the Duke University School
of Medicine and Durham VA Medical Center IACUC.
Female C57BL/6 mice were purchased from Charles River
Laboratories (Raleigh, NC). Animals were maintained in a
specific pathogen-free environment and used for experi-
ments at age 8 to 12 weeks.
Tumor cells
D5lacZ is a derivative of the B16 melanoma cell line which
stably expresses the lacZ gene product β-galactosidase.
These cells are cultured in complete medium (CM, RPMI
1640, 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM
non-essential amino acids, 1 mM sodium pyruvate,
100 U/ml penicillin, 100 mg/ml streptomycin, 0.5 μg/ml
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mercaptoethanol) (Invitrogen, Grand Island, NY).
Preparation of antibody
Hybridoma cells expressing anti-CD25 PC61 or Y13
(anti-HaRas) control mAbs were cultured in Hybridoma
Serum-Free Media (Invitrogen) with 1% Penicillin/
Streptomycin (Invitrogen), at the Duke University Cell
Culture Facility. Antibodies were purified by ammo-
nium sulfate precipitation of supernatants.
Regulatory T-cell inactivation
The efficacy of the anti-CD25 PC61 mAb to deplete
Treg was tested in both naïve and tumor bearing mice.
250 μg/0.5 ml Hank’s Balanced Salt Solution (HBSS) of
PC61 or Y13 mAb was injected intraperitoneally into
naive C3H/HeN mice. One mouse from each group was
sacrificed at 7, 14, 21, 28, and 42 days after antibody
injection. Spleens were harvested and enriched for T
cells using the EasySep T-cell isolation kit (Stemcell
Technologies, Vancouver, BC, Canada). T cells were
stained for fluorescence-activated cell sorting (FACS)
analysis with FITC-CD4, APC-CD25, and PE-FoxP3,
respectively (eBioscience, San Diego, CA). Frequencies
of CD4+CD25+FoxP3+ populations in both groups were
compared to determine Treg inactivation. In order to
confirm that the PC61 mAb was also effective in
tumor-bearing mice, a dose of 0.25×106 D5lacZ cells
was injected via tail vein into C57BL/6 mice on Day 0.
On Day 2, 250 μg/0.5 ml of PC61 or Y13 mAb were
administered intraperitoneally. Mice were sacrificed at
3, 10, 20 days after tumor inoculation and Treg inacti-
vation was determined by FACS.
Dendritic cell preparation
DCs were generated from the femoral and tibial bone
marrow cells of female C57BL/6 mice, After depletion of
B and T cells using monoclonal antibody-coated magnetic
beads (Invitrogen Dynal AS, Oslo, Norway), cells were
cultured at 0.5×106 cells/ml in CM supplemented with
10 ng/ml granulocyte macrophage colony-stimulating
factor (GM-CSF) and 10 ng/ml IL-4 (Peprotech, Rocky
Hill, NJ). On day 6, DCs were harvested and cultured in
fresh CM+GM-CSF+IL-4 at 1×106 cells/ml. One day 7,
25 ng/ml of lipopolysaccharide (Sigma-Aldrich, Saint
Louis, MO) was added to the cultured cells to stimulate
DC maturation. After 24 hours, DCs were collected for
electrofusion.
Electrofusion of dendritic cell-tumor hybrids
Irradiated D5lacZ cells (100 Gy) were stained green with
intracellular carboxyfluoroscein diacetate succinimidyl
ester (CFSE; Molecular Probes, OR) and combined at a
1:1 ratio with matured DCs. Cells were washed inprefusion media and suspended in fusion media at a
concentration of 2×107 cells/ml. Cells were fused using
the ECM 2001 pulse generator (BTX instruments, San
Diego, CA). First, a low voltage alternating current of
120 V/cm for 10 seconds was applied to achieve align-
ment and chain formation. Then, cells were pulsed with
a high voltage direct current of 1100 V/cm for 25 μs to
cause reversible breakdown of cell membranes. The
resulting hybrid cells were cultured overnight in CM at
37°C with 5% CO2. After 24 hours, the adherent cell
population containing the fusion hybrids was harvested
and prepared for vaccination.
Animal studies
0.25×106 D5lacZ cells/200μl of Hank’s Balanced Salt Solu-
tion were injected via tail vein into C57BL/6 mice to estab-
lish pulmonary metastases for this therapeutic model. After
2 days, 250 μg/0.5 ml HBSS of PC61 or Y13 mAb were
injected into mice. One day later, animals were vaccinated
with 0.3×106 cells/10 μl HBSS of fusion cells that were
injected into their inguinal lymph nodes. IL-12 (0.2 μg/
0.5 ml HBSS) was administered intraperitoneally daily for
4 days, starting on the day of vaccination. Lungs and
spleens of mice were harvested 3 weeks after establishment
of pulmonary metastases. Metastases were enumerated and
splenocytes were frozen for further analysis.
ELISPOT analyses
The D5lacZ cell line, which was used as a stimulator, was
cultured in the presence of 0.1 μg/ml (1,000 U/ml) murine
IFN-γ for 3 days to up-regulate the expression of MHC
class I and II molecules. CD4+ and CD8+ T cells were
separately enriched from frozen spleen cells using their re-
spective EasySep T cell isolation kits (Stemcell Technolo-
gies). IFN-γ cytokine secretion from stimulated T cells
was detected according to the ELISPOT kit protocol pro-
vided by the manufacturer (BD Biosciences, San Jose,
CA). Briefly, 96-well nitrocellulose plates were coated with
purified anti-mouse IFN-γ and left overnight at 4°C. The
next day, plates were washed, and blocked with CM for
2 hours. Effector cells (0.2×106/well) were then co-
cultured with stimulator cells at a ratio of 5:1 and incu-
bated for 24 hours at 37°C, 5% CO2. After lysis of the cells,
plates were developed with biotinylated detection anti-
body, enzyme conjugate ExtrAvidin-Alkaline phosphatase,
1/10000 dilution (Sigma-Aldrich), and substrate solution
BCIP/NBT phosphatase (KPL, Gaithersburg, MD). Spots
were enumerated using a CTL-ImmunoSpot analyzer
(Shaker Heights, OH).
Results
PC61-mediated inactivation of Tregs
In a first set of experiments, the efficacy of the anti-
CD25 PC61 mAb to inactivate Tregs was tested in both
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(control) mAb was injected intraperitoneally into naive
C3H/HeN mice. One mouse from each group was
sacrificed at 7, 14, 21, 28, and 42 days after antibody
injection. Spleens were harvested and enriched for T
cells. T cells were stained with anti-CD4, anti-CD25, and
anti-FoxP3 antibodies and analyzed by FACS (data not
shown). Frequencies of CD4+CD25+FoxP3+ Tregs in
both groups were compared and the results are shown
in Table 1 (top). We observed that 95-98% of Tregs were
undetectable for up to 21 days. After 28 days, the Treg
population began to return to 50% of the original level
and Treg frequencies increased to 64% of baseline after
42 days, which is conceivable given a PC61 half-life of
20 days in vivo.
Next, we determined the efficacy of PC61-mediated
Treg inactivation in D5lacZ tumor bearing C57BL/6
mice to confirm that tumor-induced Tregs are also being
inhibited by PC61 administration. D5lacZ cells were
injected via tail vein into C57BL/6 mice to establish pul-
monary metastases and after 2 days, PC61 or Y13 mAbs
were administered intraperitoneally. Mice were sacrificed
at 3, 10, 20 days after tumor inoculation and Treg inacti-
vation was determined by FACS. As can be seen in
Table 1 (bottom), 87% of Tregs were inactivated as early
as 1 day after administration of PC61 mAb (day 3) and
remained at that level (86%) until day 20, the typical
duration of our tumor vaccination studies.
DC-tumor cell fusion efficiency
The electrofusion rate between DCs and D5lacZ melan-
oma cells was determined by FACS analysis. As presented
in Figure 1A (top), DCs appeared to be well-differentiatedTable 1 Assessment of PC61-mediated Treg inactivation
Naive mice










(Top) Naïve C3H/HeN mice were injected intraperitoneally with PC61 mAb or
Y13 control mAb, respectively. Mice were sacrificed at the indicated time
points and splenocytes were analyzed by FACS after staining with anti-CD4,
anti-CD25, and anti-FoxP3. The percentage of triple-positive cells is presented.
(Bottom) Lung metastases were established in C57BL/6 mice via tail vein
injection of D5lacZ cells. 2 days later, animals received intraperitoneal
injections of PC61 or Y13 mAbs. Mice were sacrificed at the indicated time
points, splenocytes were analyzed by FACS as described above and the
percentage of triple-positive cells was determined.and expressed high levels of maturation marker CD80,
CD86 and intercellular adhesion molecule (ICAM, CD54).
In contrast, cultured D5lacZ expressed none of the above-
mentioned DC markers (data not shown). Prior to fusion,
D5lacZ cells were intracellularly and covalently labeled
with the green fluorescent dye CFSE. After electrofusion,
cells were incubated in media and adherent fusion cells
were harvested 24 hours later. Cells were stained with
mAbs against DC markers CD80, CD86 and ICAM, for
FACS analysis. Figure 1A (bottom) shows the percentages
of double-positive fusion cells (upper right quadrant of
dot plots). The observed fusion efficacy of about 55% was
well in agreement with fusions yields routinely obtained in
our laboratory. In contrast, while 78% of DCs were MHC
class I positive and 84% of DCs were MHC class II posi-
tive (Figure 1B, top), only 26.6% of fusion cells expressed
MHC class I molecules and only 28.0% of fusion cells
were MHC class II positive (Figure 1B, bottom).
DC-Tumor cell fusion vaccine efficacy after inactivation of
Treg
Next, we determined whether PC61-mediated inactiva-
tion of Tregs was capable of enhancing the efficacy of
DC/tumor cell fusion vaccination in the B16 murine
melanoma model (Figure 2). A subset of animals was
also treated with fusion vaccine plus intraperitoneal IL-
12, the current ‘gold standard’ in our murine melanoma
model. Pulmonary metastases were established via tail
vein injection of D5lacZ cells three days before intranodal
vaccine administration and mice were sacrificed after
21 days. Mice were treated with saline (−), intraperitoneal
Y13 control mAb (Y13), intraperitoneal PC61 mAb
(PC61), intraperitoneal IL-12 (IL-12), Y13 mAb plus DC/
D5lacZ fusion cells (Y13+FC), PC61 mAB plus DC/
D5lacZ fusion cells (PC+FC), and intraperitoneal IL-12
plus DC/D5lacZ fusion cells (IL-12+FC). There was no
statistically significant difference in pulmonary metastasis
counts between untreated (206.4 ± 50.0), Y13- or PC61-
treated animals (198.5 ± 59.17 versus 199.3 ± 49.16).
However, mice treated with fusion vaccine and PC61 mAb
had significantly fewer metastases (99.3 ± 89.2) than ani-
mals treated with Y13 control mAb and fusion vaccine
(134 ± 74.2) (p = 0.0397) and animals treated with PC61
mAb alone (199.3 ± 49.16) (p = 0.002). We conclude that
PC61 treatment synergized with fusion vaccination to in-
crease vaccine efficacy, albeit to a lesser degree than treat-
ment with fusion vaccine and IL-12 (4.7 ± 10.76).
ELISPOT Analysis of IFN-γ secretion by vaccine induced
CD4+ and CD8+ T cells
After observing that PC61-based Treg inactivation sig-
nificantly enhanced the tumor regression triggered by
fusion vaccination, we sought to understand the immune
mechanism by which this improvement occurred. Spleens
Figure 1 FACS analysis of DCs and subsequent confirmation of DC-D5LacZ fusion hybrids. (A) Electrofusion of DCs and D5lacZ cells.
(Top panel) Phenotype of DCs at day 0 (black histograms) and day 8 (grey histograms) of culture. (Bottom panel) Prior to fusion, D5LacZ were
intracellularly and covalently labeled with CFSE. 24 hours after fusion, adherent cells were harvested and stained with DC markers as indicated.
Numbers in the upper right quadrant represent percentages of double-positive fusion hybrids. (B) MHC class I (H2-kb) and MHC class II (I-Ab)
expression of DCs and DC-tumor fusion cells.
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Figure 2 Effects of Treg-inactivation on the efficacy of DC-
tumor cell fusion vaccination. Lung metastases were established
in C57BL/6 mice via tail vein injection of D5lacZ cells. After 2 days,
mice received intraperitoneal injections of saline (−), Y13 mAb (Y13),
or PC61 mAb (PC61). On day 3, DC-tumor fusion cells (FC) were
delivered intranodally. IL-12 was administered intraperitoneally daily
for 4 days, starting on the day of vaccination. Mice were sacrificed
and lung metastases were enumerated after 21 days. P-values were
calculated using the two-tailed Wilcoxon rank sum test. The number
(n) of animals used in each group is indicated. Results are presented
as box plots in which the median, the 25 percentile, the 75
percentile, as well as minimum and maximum of each group
are shown.
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T cells were isolated and stimulated with D5LacZ tumor
cells in IFN-γ ELISPOT assays (Figure 3B). Before using
D5lacZ cells as stimulators, MHC class I and class II ex-
pression was induced by treatment with IFN-γ and ana-
lyzed by FACS (Figure 3A). Data from three independent
experiments were averaged, and the results reveal an
overall difference in the number of vaccine-induced IFN-γ
secreting CD4+ T cells between fusion vaccine plus Y13
mAb treatment (Y13 + FC) and fusion vaccine plus PC61
mAb treatment (PC61+FC) (37 ± 26 versus 243 ± 120)
(Figure 3A). In contrast, our data indicate that there was
no statistically significant difference in the number of
vaccine-induced CD8+ T cells between the fusion + Y13
and fusion + PC61 conditions (mean=4, SD=1.54 for
fusion+Y13; mean=11, SD=5.72 for fusion+PC61)
(Figure 4B).
Combination treatment with PC61 mAb and
intraperitoneal mIL-12
Even though treatment with PC mAb demonstrated
therapeutic efficacy against murine melanoma, it was
not capable of completely eradicating pulmonary metas-
tases. On the other hand, IL-12 administration has
resulted in severe toxicity in cancer patients, hence
preventing systemic application at therapeutically rele-
vant levels. We therefore sought to determine whetherPC61 mAb treatment could synergize with systemic IL-
12 administration in order to decrease the dose of the
cytokine needed to obtain maximal therapeutic efficacy.
Pulmonary metastases were established via tail vein in-
jection of D5lacZ cells three days before intranodal vac-
cine administration with fusion cells and mice were
sacrificed after 21 days. Mice were treated with intraper-
itoneal PC61 mAb (PC61 only), intraperitoneal IL-12
(0.1 μg) plus DC/D5lacZ fusion cells (Fusion + ½ dose),
intraperitoneal IL-12 (0.1μg), plus PC61 mAB, plus DC/
D5lacZ fusion cells (Fusion + PC61 + ½ dose IL-12), and
with intraperitoneal IL-12 (0.2 μg) plus DC/D5LacZ fu-
sion cells (Fusion + full dose IL-12).
As shown in Figure 4, treatment of mice with PC61
mAb alone did not lead to any reduction in tumor bur-
den and, expectedly, administration of 0.2 μg IL-12 (full
dose IL-12) in combination with fusion vaccine resulted
in complete eradication of lung metastases in 4 out of 5
animals. The remaining mouse in this group appears to
be an outlier. In contrast, considerable numbers of lung
metastases (35.6 ± 26.1) were observed, when the ad-
ministered dose of IL-12 was reduced by 50% (Fusion +
1/2 dose IL-12). Remarkably, treatment of animals with
PC61 mAb, half dose IL-12 and DC/D5LacZ fusion cells
led to a complete protection from lung metastasis (Fu-
sion + PC61 + ½ dose IL-12). Thus, our data provide
proof of principle that combination treatment with
PC61 mAb and systemic IL-12 can indeed lower the
dose of IL-12 necessary to obtain maximal therapeutic
efficacy and may therefore represent a viable strategy to
reduce IL-12 mediated toxicity in a clinical setting.
Discussion
The aim of this study was to examine whether PC61
mAb-mediated functional inactivation of Tregs would
enhance the potency of a DC/tumor fusion-based vac-
cine in a murine melanoma model with established pul-
monary metastases. In agreement with previous reports,
we were able to demonstrate that administration of mAb
PC61 causes significant inactivation of Tregs that is
maintained for about 3 weeks until the Treg population
returns [20,21,25]. It is important to note that after PC61
mAb treatment only a small portion of Tregs is actually
being depleted by phagocytes expressing the FcγRIII re-
ceptor [26]. The majority of Tregs is being functionally
inactivated through antibody-mediated blockade of IL-2
signaling [24]. Remarkably, administration of anti-CD25
in murine models and clinical studies has not resulted in
treatment related morbidity due to autoimmune disease
[25], and it is tempting to speculate that tissue-residing
Tregs might be affected to a lesser degree by antibody
treatment than Tregs found in the lymphatic system.
Furthermore, we observed that PC61 treatment en-






















Figure 4 Combination treatment with PC61 mAb and mIL-12.
Lung metastases were established in C57BL/6 mice via tail vein
injection of D5lacZ cells. After 2 days, mice received intraperitoneal
injections of 250 μg/0.5 ml PC61 mAb (PC61 only, Fusion + PC61 +
½ dose IL-12). On day 3, DC-tumor fusion cells (Fusion) were
delivered intranodally. IL-12 was administered intraperitoneally daily
for 4 days at 0.2 μg/0.5 ml (full dose) or 0.1 μg/0.5 ml (1/2 dose),
respectively, starting on the day of vaccination. Mice were sacrificed

















































Figure 3 IFN-γ ELISPOT analysis. (A) IFN-γ- stimulated D5lacZ tumor cells were used as stimulators in ELISPOT assays. Up-regulation of MHC
class I (H2-kb) and class II (I-Ab) was confirmed by FACS. Isotypic controls (solid lines), MHC expression in the absence of IFN-γ (filled grey
histograms), and MHC expression of D5lacZ tumor cells that had been treated for 72 hours with IFN-γ at 1,000 U/ml of media (dotted lines) are
presented in our FACS analyses. (B) Frequencies of IFN-γ-secreting CD4+ and CD8+ T-effector cells in response to D5lacZ tumor stimulation. CD4+
and CD8+ T cells were isolated from spleens that were harvested from naïve mice (naïve), mice treated with control mAb and DC/D5lacZ fusion cells
(Y13+FC), mice treated with PC61 mAb and fusion cells (PC61+FC), and mice treated with systemic IL-12 and fusion cells (IL-12+FC). IFN-γ secreting
cells were enumerated without stimulation (−) or after stimulation with D5lacZ cells (stimulators). 2.5×105 T cells (responders) per well were stimulated
at a responder to stimulator ratio of 5:1. ELISPOT assays were performed in triplicates and averaged data of 3 independent experiments are shown.
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cells despite their transient expression of CD25
molecules. These observations are in disagreement with
a recent report which examined the ability of the hu-
manized anti-IL-2Rα mAb daclizumab to deplete Tregs
in metastatic melanoma patients receiving antitumor
vaccination with peptide- and KLH (keyhole limpet
hemocyanin)-loaded DCs [27]. The authors demon-
strated that while Tregs were effectively depleted and
anti-tumor T cells were induced, daclizumab impaired
the acquisition of T-effector function in vivo. A different
report as well as our own data suggest otherwise. First,
Sampson et al. [23] showed that depletion of Tregs
correlated with increased vaccine-stimulated humoral
immunity in glioblastoma patients during temozolomide-
induced lymphopenia. Second, after mAb PC61-treatment,
we observed increased frequencies of vaccine-induced
CD4+ T cells that secreted IFN-γ upon stimulation with
tumor cells. And last, administration of mAb PC61 greatly
enhanced the efficacy of vaccination with fusion cells and
systemic IL-12 which clearly indicates that PC61 does not
seem to have any immunoinhibitory effects.
In our studies, the vaccine-induced immune response
after treatment with PC61 and fusion cells consisted pri-
marily of tumor-specific CD4+ T cells. This is not with-
out precedence and in accordance with several studies,
which have demonstrated that CD4+ T cells play apivotal effector role during tumor rejection [28]. While
the mechanisms responsible for the observed antitumor
effect are still being explored, possible effector mechanisms
may include Fas/FasL-mediated killing [29], interferon-
γ–mediated angiostasis [30], interferon-γ–mediated
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recruitment or activation of innate effectors, including
macrophages and eosinophils [32].
Even though, CD4+ T-effector cells may play an im-
portant role in anti-tumor responses, the lack of
vaccine-induced CD8+ cytotoxic T cells in the presence
of a potent Th-1-biased T-helper cell response is unset-
tling and may indicate that efficient cross-presentation
of tumor-associated antigens did not occur in DC/tumor
fusions. B16 melanoma cells are poorly immunogenic
due to downregulation of transporters associated with
antigen processing (TAP-1 and TAP-2) [33], resulting in
reduced MHC class I expression and a diminished ability to
present antigens to CD8+ T cells. TAP downregulation has
been observed in multiple human malignancies and plays a
critical role in the clinical course of malignant melanoma
[34]. It is conceivable that factors leading to downregulation
of TAPs in B16 melanoma cells may act in a negative trans-
dominant fashion in fusion cells, thereby impairing MHC
class I presentation and hence the induction of CD8+ Tcells
by DC/tumor cell hybrids. If this was true, the observed in-
duction of CD8+ T-cell responses by fusion vaccine in the
presence of IL-12 would be either a result of IFN-γ induced
antigen-presentation by fusion cells [35] or due to stimula-
tion of tumor-infiltrating lymphocytes and T cells in
draining lymph nodes, as has been described [36,37].
Therefore, strategies aiming to overexpress TAP1 and
TAP2 in fusion cells may represent a promising new ap-
proach to increase the immunogenicity of fusion vaccines.
Systemic administration of IL-12 in combination with
DC-tumor fusion vaccination has demonstrated impres-
sive anti-tumor responses in murine models. In cancer
patients, however, IL-12 administration and the con-
comitant induction of high IFN-γ levels have resulted in
severe toxicity including adverse hematopoietic, intes-
tinal, hepatic, and pulmonary side effects, which pre-
cludes systemic application of IL-12 at therapeutically
relevant levels [38]. Here, we provide proof of principle
that combination treatment consisting of mAb PC61
and systemic IL-12 can lower the dose of cytokine ne-
cessary to obtain maximal therapeutic efficacy and may
therefore represent a viable strategy to reduce IL-12 me-
diated toxicity in a clinical setting. Further studies will be
needed to determine the therapeutic window of this novel
approach.ken together, we conclude that PC61-mediated
inactivation of Tregs is a viable strategy to improve the ef-
ficacy of DC/tumor fusion vaccination and that combining
vaccination with Treg depletion and systemic administra-
tion of IL-12 may represent a novel approach to unleash
the full potential of DC/tumor fusion vaccines.
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